Skip to content
Parakho

Lupin Ltd

NSE LUPINBSE 500257lupin.com

Q1 FY27, unaudited

Revenue
₹7,171.90 Cr
Profit after tax
₹2,714.60 Cr

As filed with the exchange, standalone basis.

Statement of profit and loss

Figures in ₹ crore, reproduced from the results data files the company filed with NSE under Regulation 33 of the SEBI (LODR) Regulations. Nothing is restated, adjusted or estimated.

Statement of profit and loss, standalone basis
₹ croreQ1 FY27vs a year agoFY26
Revenue from operations7,171.90+25.63%19,512.66
Other income102.48+89.29%312.77
Total income7,274.38+26.23%19,825.43
Employee benefit expense719.69+11.77%2,544.88
Finance costs35.56+88.15%121.47
Depreciation & amortisation190.01+7.51%707.18
Total expenses3,664.32+15.43%12,537.75
Profit before tax3,610.06+39.48%7,694.25
Tax expense895.46+94.63%1,327.69
Profit after tax2,714.60+27.56%6,366.56
Total comprehensive income2,721.66+28.01%6,349.48
Earnings per share
Earnings per share, basic₹59.37₹139.38
Earnings per share, diluted₹59.27₹139.01

Q1 FY27 — unaudited, from the company’s filing with NSE. Source

Q1 FY26, the year-ago base — unaudited, from the company’s filing with NSE. Source

FY26 — from the company’s filing with NSE. Source

Earnings call

Q4 FY26

Lupin reported Q4 FY26 revenue growth of 32% YoY to Rs. 7,475 crores and EBITDA growth of 68% YoY to Rs. 2,171 crores, marking its 15th consecutive quarter of growth. For the full year, revenue grew 23% YoY to Rs. 27,958 crores with EBITDA margins at 29.7%, driven by strength in the US business which grew 40% YoY to USD 1,318 million, alongside double-digit growth in India, Other Developed Markets and Emerging Markets. Management outlined plans for FY27 including new product launches such as Ravicti, Saxenda and Pegfilgrastim, while flagging anticipated competition in Tolvaptan and Mirabegron.

Generated by AI from the filed transcript; every statement on the full page carries its verbatim quote. Read the cited summary

Filings

12 shown · 83 published by the exchange

BSE corporate announcements, classified by Parakho. The exchange’s own category is kept alongside our classification so a reclassification never rewrites history.

Page generated from filings held to 25 Aug 2026.